TY  - GEN
AU  - Dummer,Reinhard
AU  - Ascierto,Paolo A
AU  - Gogas,Helen J
AU  - Arance,Ana
AU  - Mandala,Mario
AU  - Liszkay,Gabriella
AU  - Garbe,Claus
AU  - Schadendorf,Dirk
AU  - Krajsova,Ivana
AU  - Gutzmer,Ralf
AU  - Chiarion Sileni,Vanna
AU  - Dutriaux,Caroline
AU  - de Groot,Jan Willem B
AU  - Yamazaki,Naoya
AU  - Loquai,Carmen
AU  - Moutouh-de Parseval,Laure A
AU  - Pickard,Michael D
AU  - Sandor,Victor
AU  - Robert,Caroline
AU  - Flaherty,Keith T
TI  - Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
SN  - 1474-5488
PY  - 2019///0617
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Benzimidazoles
KW  - administration & dosage
KW  - Biomarkers, Tumor
KW  - genetics
KW  - Carbamates
KW  - Disease Progression
KW  - Female
KW  - Genetic Predisposition to Disease
KW  - Humans
KW  - Male
KW  - Melanoma
KW  - drug therapy
KW  - Middle Aged
KW  - Mutation
KW  - Phenotype
KW  - Progression-Free Survival
KW  - Protein Kinase Inhibitors
KW  - Proto-Oncogene Proteins B-raf
KW  - Skin Neoplasms
KW  - Sulfonamides
KW  - Time Factors
KW  - Vemurafenib
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/S1470-2045(18)30497-2
ER  -